Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Lexaria Bioscience Corp.

    NASDAQ: LEXX · Real-Time Price · USD
    0.85
    0.00 (0.12%)
    At close: Jun 30, 2025, 3:59 PM
    0.87
    2.05%
    After-hours: Jun 30, 2025, 04:00 PM EDT
    0.12%
    Bid 0.83
    Market Cap 16.61M
    Revenue (ttm) 525.92K
    Net Income (ttm) -9.38M
    EPS (ttm) -0.61
    PE Ratio (ttm) -1.4
    Forward PE -1.53
    Analyst Buy
    Ask 1.02
    Volume 54,779
    Avg. Volume (20D) 109,672
    Open 0.85
    Previous Close 0.85
    Day's Range 0.85 - 0.85
    52-Week Range 0.82 - 4.38
    Beta 0.94

    About LEXX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol LEXX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for LEXX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 months ago
    -20.12%
    Lexaria Bioscience shares are trading lower. The c... Unlock content with Pro Subscription
    5 months ago
    -6.31%
    Lexaria Bioscience shares are trading lower. The company announced partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3.
    news image

    1 week ago · accessnewswire.com

    Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

    New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...

    news image

    2 weeks ago · accessnewswire.com

    Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

    Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R))  Lexaria has now demonstrated, in distinct human clinical studies,...

    news image

    3 weeks ago · accessnewswire.com

    Lexaria Attending BIO International Convention

    Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global inn...

    news image

    1 month ago · thenewswire.com

    Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

    Kelowna, British Columbia – TheNewswire - May 12, 2025 - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this updat...

    news image

    2 months ago · thenewswire.com

    Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

    Kelowna, British Columbia – April 28, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today annou...

    news image

    2 months ago · thenewswire.com

    Lexaria Announces $2 Million Registered Direct Offering of Common Stock

    Kelowna, British Columbia – TheNewswire - April 25, 2025 – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today annou...

    news image

    2 months ago · accessnewswire.com

    Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

    Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 2...

    news image

    2 months ago · thenewswire.com

    Lexaria Updates its Ongoing Human Study GLP-1-H24-4

    Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss    Kelowna, British Columbia – April 3, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Comp...

    news image

    2 months ago · accessnewswire.com

    Lexaria's Human GLP-1 Study #5 Begins Dosing

    Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April ...

    Add to Watchlist